Research Funded To Date
The Ben and Catherine Ivy Foundation is dedicated to finding a cure for brain cancer. We strive in improve the quality of life and increase the life expectancy of those diagnosed with brain cancer by funding promising research that creates more diagnostics and treatments for patients.
Since 2008, we have funded 33 separate institutions with over 107 different research grants totaling over $150 million. These grants have involved research in phase 0 clinical trials, biomarkers, genomics, imaging, immunotherapy, stem cell, vaccines, and the development of possible new drugs.
2017
NEUROLOGICAL SCIENCES INTERNSHIP PROGRAM AT TGEN DESIGNED TO GIVE HIGH SCHOOL AND UNDERGRADUATE STUDENTS INTENSIVE, HANDS-ON RESEARCH EXPERIENCE WORKING ALONGSIDE A MENTOR-SCIENTIST TO LEARN ABOUT TRANSLATIONAL RESEARCH WHILE INVESTIGATING QUESTIONS WITHIN THE NEUROLOGICAL SCIENCES.
PI: Julie Euber
Manager of Education and Outreach
Translational Genomics Research Institute (TGen)
Award: 77,746
CREATION OF THE IVY HIGH GRADE GLIOMA DATABASE (HGGDB) FOR COLLECTING AND SHARING CLINICAL AND GENOMIC DATA OF PATIENTS WITH HIGH GRADE GLIOMAS. THE CLOUD BASED PLATFORM WILL CONTAIN DATA FROM THE IVY CONSORTIUM INSTITUTIONS TO ADDRESS SECURITY, SCALABILITY AND COLLABORATION. IT ALSO WILL PROVIDE AN APPLICATION PROGRAMMING INTERFACE (API), AFFORDING A DIRECT INTERFACE TO THE DATABASE FOR AUTOMATED COMPUTER SYSTEMS AND TOOLS FOR BUILDING AND USING APPLICATION SOFTWARE.
PI: Nicholas Butowski, M.D.
Professor | Neurological Surgery
Director, Translational Research | Neuro-Oncology
Director, UCNS Fellowship | Neuro-Oncology
Chair, CNS Tumors Site Committee | UCSF Helen Diller Family Comprehensive Cancer Center
University of California San Francisco
PRECLINICAL AND CLINICAL DEVELOPMENT OF NEURAL STEM CELLS (NSC) DELIVERED AS AN ONCOLYTIC VIROTHERAPY FOR NEWLY DIAGNOSED GLIOMA PATIENTS TO OPTIMIZE TARGETED GLIOMA TREATMENT WITH TUMOR-TROPIC NSCs THAT PRODUCE CONDITIONALLY REPLICATING ONCOLYTIC ADENOVIRUS (CRAd).
PI: Karen S. Aboody, MD
Professor, Department of Developmental & Stem Cell Biology
Scientific Leader, Neuro-Oncology Disease Team
City of Hope NCI Designated Comprehensive Cancer Center & Beckman Research Institute
Duarte, CA
ENGINEERING DE NOVO ANTITUMOR IMMUNITY USING PATIENT-SPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR)-MODIFIED T CELLS. DEVELOPMENT OF A NEW CLASS OF CARS EXPLOITING THE BROAD AND SELECTIVE GBM BINDING PROPERTIES OF THE SCORPION TOXIN PEPTIDE CHLOROTOXIN (CTX) AND EVALUATE THE POTENTIAL OF A CTX-CAR TO LIMIT GBM ANTIGEN ESCAPE.
PI: Christine E. Brown, PH.D.
Associate Director, T Cell Therapeutics Research Laboratory
Departments of Hematology & Hematopoietic Cell Transplantation and Immuno-Oncology
City of Hope
Duarte, CA